| Previous close | 4.3000 |
| Open | 4.3000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 105.00 |
| Expiry date | 2024-09-20 |
| Day's range | 4.3000 - 4.3000 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
PR NewswireJazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that thirteen abstracts, including five late-breaking abstracts, featuring new data from across its sleep medicine portfolio will be presented at SLEEP 2024, the 38th annual meeting of the Associated Professional Sleep Societies being held June 1-5, 2024, in Houston, Texas.
- PR Newswire
Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the following investor conferences:
- PR Newswire
Zanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review of the Biologics License Application (BLA) for zanidatamab, the human epidermal growth factor receptor 2 (HER2)-targeted bispecific antibody, for the treatment of previously treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC). Under the Prescription Drug User Fee Act (PDUFA), FDA has set a target action date
